YONDELIS® (trabectedin) is an anticancer agent of marine origin originally isolated from the ascidian Ecteinascidia turbinata, which was found in the Caribbean Sea. Currently, YONDELIS® is chemically produced through a semisynthetic process that involves an initial step of fermentation of the bacterium Pseudomonas fluorescens. It is the first marine-derived drug to be approved in oncology.


YONDELIS® (trabectedin) has been approved in Europe for the treatment of advanced soft tissue sarcoma and recurrent platinum-sensitive ovarian cancer (in combination with DOXIL®/Caelyx®). The drug has been approved by the US Food and Drug Administration (US FDA) and by the Japanese authorities for soft tissue sarcoma in the US and Japan, respectively. The European Commission (EC) and the US Food and Drug Administration (US FDA) YONDELIS® (trabectedin) granted orphan drug designation to trabectedin for the treatment of soft tissue sarcoma and ovarian cancer, and the drug also obtained orphan drug designation in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) for soft tissue sarcoma.

Under license agreements, Janssen Products holds the rights to develop YONDELIS® (trabectedin) in the US and rest of the world except for Japan, where Taiho Pharmaceutical has the rights to develop and commercialize the drug, and Europe where PharmaMar develops and markets YONDELIS® (trabectedin).

To know more about the clinical development of YONDELIS® (trabectedin) please explore our pipeline:

Know more

To know more about YONDELIS® (trabectedin) please go to www.allthepowerofthesea.com.

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Science & Innovation

Our strong commitment to oncology translational research along with our deep understanding of the marine biodiversity of our oceans is placing us at the head of marine biotechnology.


If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom